Lamivudine is a prescription nucleoside reverse transcriptase inhibitor (NRTI) that is used in combination with other drugs as antiviral treatment for human immunodeficiency virus type-1 (HIV-1) and as a monotherapy for hepatitis B virus (HBV). It reduces viral load and subsequently reduces disease signs and symptoms, increases CD4+ cell count, improves patient's quality of life, and can help prolong life. The ability to reduce viral load, rather than eradicate the virus in a human host, classifies lamivudine as a virustatic, rather than a virucidal agent. It is prescribed as part of other combination therapies. Lamivudine is globally important as first-line NRTI therapy; it is currently on the World Health Organization (WHO) "List of Essential Medications."
Lamivudine, also termed 2',3'-Dideoxy-3'-thiacytidine or 3TC, was approved to treat HIV-1 in 1995, then for HBV in 1998. The currently manufactured lamivudine (3TC) is an isolated unnatural L-(-) enantiomer that was found to be more potent and less cytotoxic than the originally studied racemic mixture termed BCH-189. Ensuing studies of lamivudine have shown that it is most efficacious as a monotherapy for HBV as well as in an HIV regimen that includes multiple antiretroviral therapies. It is used in combination with two or more antivirals to prevent rapid mutations that can lead to drug resistance in HIV-1 patients, specifically via the M184V reverse transcriptase single substitution mutation that has shown to occur in as little as 8-weeks of mono- or combination antiviral therapy that contains lamivudine (3TC).
Treatment of HIV-1 by lamivudine is in combination with zanuvidine, didanosine, raltegravir, or zalcitabine. The newest combination approved by the US Food and Drug Administration (FDA) in 2019, includes 300 mg of 3TC and 50 mg of dolutegravir (DTC), an integrase inhibitor, and is considered a complete therapy regimen for adults who are antiretroviral treatment naïve. This newer dual therapy approach is proving just as effective as 3 or 4 drug regimens.
As a virustatic agent, lamivudine has been studied as a possible treatment for SARS-CoV. However, in all known published trials and research, lamivudine has not been shown to be an efficacious treatment for SARS-CoV.
Lamivudine is a dideoxynucleoside cytosine analog that inhibits viral DNA synthesis via reverse transcriptase DNA chain termination post phosphorylation. Once inside the cell, lamivudine, 2'-deoxy-3'-thiacytidine, is metabolized to the triphosphate form, lamivudine triphosphate (abbreviated as 3TC-TP or L-TP), and the monophosphate form, lamivudine monophosphate (abbreviated as 3TC-MP or L-MP), during intracellular kinase phosphorylation. Both forms, L-TP and L-MP, inhibit viral DNA synthesis. It is advantageous as an antiviral drug because it is primarily not recognized by human polymerase as a substrate. As an L-(-)-nucleoside enantiomer instead of D-enantiomer, active lamivudine (3TC) is not primarily recognized by human polymerases as a substrate, but actively competes with natural cytidine triphosphate to inhibit reverse transcriptase DNA synthesis seen in both HIV-1 and HBV infection. The triphosphate metabolite can also weakly inhibit mammalian DNA polymerase (alpha and beta types) and mitochondrial DNA (mtDNA) polymerase.
Lamivudine is absorbed rapidly, with maximum lamivudine concentration 0.5 to 1.5 hours following oral dose administration and absolute bioavailability of approximately 82% in adults and 68% in children. Lamivudine can be taken with or without food. While the systemic exposure of lamivudine does not change with food intake, taking lamivudine with food slows the absorption rate by 40%. Lamivudine is manufactured as an oral liquid and tablet form and has equitable bioavailability in adults. The solid tablet is preferred in children because bioavailability is 40% lower in children using the oral liquid form. While both doses of the solid tablet have the similar steady-state concentrations and therapeutic effects, the larger dose, 300mg taken once daily, has shown to have larger trough and maximum serum levels and is less consistent throughout the day as compared to the smaller 150mg tablet taken twice daily.
Lamivudine distributes into the total body fluid/extravascular spaces. It has a long intracellular half-life of as long as 15.5 hours for HIV infected cell and 19 hours for HBV infected cell. However, viral replication site reservoirs showed varying pharmacokinetics. Lamivudine has shown to have a longer half-life and higher IC50 after the first dose in seminal mononuclear cells and the female genital tract. Conversely, the cerebral spinal fluid has shown minimal transmission of lamivudine across the blood-brain barrier, especially in adults. Lamivudine freely traverses the placenta, often presenting with exceedingly high concentrations, as well as is readily found in breast milk.
Lamivudine is eliminated in the urine as an active organic cation secretion. The mean elimination half-life was 5 to 7 hours. The average clearance of unaltered lamivudine is 71%, with 5 to 10% excreted as trans-sulfoxide. This clearance indicates the necessity for sufficient kidney function in the patient, and dosing should be adjusted accordingly. Dialysis did not significantly increase the elimination of lamivudine to warrant dose modification. Pregnant women have a 22% increase in clearance of lamivudine without leading to sub exposure. 
Lamivudine does not undergo metabolism via the CYP450 pathway and minimally binds to plasma protein. Therefore, CYP450 inducers and inhibitors will not affect its metabolism, nor does it have many drug interactions with those that are protein-bound. While lamivudine has some drug-drug interactions, like interferon-alpha-blockers, ribavirin, zidovudine, and drugs that inhibit MATE-1, MATE-2K, OCT2transporters, like trimethoprim and indinavir, which increases the plasma concentration of lamivudine, no interactions have clinical significance. One exception is sorbitol, which demonstrates dose-dependent decreases in the maximum serum concentration of lamivudine.
There are no known pharmacokinetic differences related to gender or race. Pharmacokinetic differences have not been sufficiently studied to extrapolate adjustments for either older age or glomerular filtration rate (GFR).
Lamivudine is available in 150 mg scored tablets, 300 mg tablets, and also as 5 mg or 10 mg/ml oral solutions. It may be taken with or without food and should be stored at room temperature. The patient should take a missed dose when they remember, but doses should not be doubled-up.
Doses should be adjusted accordingly for patient kidney function. Creatinine clearance greater than or equal to 50 mL/min should have a lamivudine dose of 150 mg twice per day or 300 mg once per day. Creatinine clearance of 30 to 49 mL/min should have a lamivudine dose of 150 mg once per day. If a patient's creatinine clearance is between 15 to 29 mL/min, they should receive 150 mg as a first dose, then 100 mg per day thereafter. Creatinine clearance of 5 to 14 mL/min equates to 150 mg as a first dose, then 50 mg per day thereafter. Creatinine clearance less than 5 mL/min, the patient would receive 50 mg as the first dose and then 25 mg per day.
Additional dosing is not necessary after either 4-hour routine hemodialysis or peritoneal dialysis.
Pediatric patients should be able to swallow tablets safely and should use a separate dosing schedule. If the child is unable to swallow the tablet, oral solution dosage may need to increase because of the decrease in bioavailability.
Lower dose lamivudine is a once-daily 100 mg dose of lamivudine only indicated for HBV treatment without co-infection of HIV-1. Pre-administration testing and counseling are necessary, as well as subsequent testing while taking lower dose lamivudine.
Care is necessary if the patient is currently resistant to other previously prescribed antiviral medications. Chronic co-administration with sorbitol should be avoided to prevent a decrease in lamivudine concentration and a resultant decrease in lamivudine potency. Pharmacokinetic changes are minor with ZDV, ddI, cotrimoxazole, and interferon-alpha-2b, so no dose adjustment is recommended. There is an increased risk of resistance with the administration of the oral solution to pediatric patients, so tablets are preferred whenever possible. Lamivudine is currently an FDA Category C drug.
Resistance to lamivudine as well as cross-resistance to other NRTI's, such as didanosine, abacavir, and emtricitabine, are seen in 10% of patients after treatment with lamivudine as a monotherapy or combined therapy after 48 weeks of treatment. While this can result in a virologic failure, clinical observations suggest that there is a benefit to continuing lamivudine treatment even when an M184V substitution mutation causes resistance.
Severe side effects include:
*Patients with HIV are already at a higher risk of acquiring Stevens-Johnson syndrome (SJS). Combined therapies also make it difficult to discern if one drug alone contributed to SJS or not. No direct cases appear in the literature.
Severe adverse effects occurred in about 5% of patients enrolled in all clinical trials. Children seemed to show a higher prevalence of fever and pancreatitis than adult patients.
Common side effects:
Lamivudine should not be administered to patients with known hypersensitivity.
NRTIs as a class have more cases with resulting hepatomegaly, with some fatalities. Lactic acidosis, a usual NRTI toxicity, is not seen as frequently with lamivudine; however, females who are obese and have been on immunotherapy for an extended time seem to be at an increased risk. If a patient presents with symptoms, lamivudine should be discontinued immediately. Additionally, the patient's liver function should be a consideration before beginning lamivudine; those with liver disease should rank as high risk.
Patients treated with interferon-alpha inhibitors with or without ribavirin when they are co-infected with HCV should be monitored closely for liver toxicities, especially hepatic decompensation due to their pyrimidine phosphorylation reduction effects. If decompensation or increase liver toxicity occurs, interferon-alpha inhibitors with or without ribavirin should be decreased or discontinued.
A patient who is using lamivudine for HBV should have testing for HIV-1, and patients with HIV-1 should be tested for HBV. If the patient has a co-infection, the lower dose lamivudine (EPIVIR-HBV) is not adequate for patients and could lead to increased antiviral resistance of either virus for both adults and children. Patients should not discontinue lamivudine while co-infected with HIV-1 and HBV. Severe, acute hepatitis B exacerbation can occur. Hepatic function (ALT levels) should be closely monitored for several months after stopping treatment, and initiation of anti-hepatitis B treatment may be appropriate with physician-guided discontinuation.
CD4+ cell count and viral load should have frequent checking to determine HIV-1 disease progression and efficacy and extent of virologic failure resulting in resistance of lamivudine in combination therapy. Patients should also receive monitoring for the development of inflammatory responses to opportunistic infections commonly seen in HIV patients (mycobacterium avium, CMV, PCP, TB) as well as autoimmune disorders within the first few months of starting combination antiviral therapy including lamivudine as symptoms of immune reconstitution syndrome.
Kidney indicators require monitored throughout treatment, especially in chronic kidney disease (CKD) patients. CKD is a natural occurrence as we age so that special attention may be necessary with the treatment of older patients.
Pediatric patients who have a history of antiviral therapy or a history of pancreatitis need monitoring for lamivudine-induced pancreatitis. Pediatric patients should also know to avoid sorbitol containing medicines when using oral lamivudine because antiviral resistance and lower virologic suppression rates can occur due to lower plasma lamivudine exposure.
Fat redistribution in a "cushingoid appearance," lipoatrophy, and insulin resistance should also be monitored in patients using NRTI's.
Lamivudine is usually well tolerated with milder toxicities compared to other NRTI's. If overdose on lamivudine occurs, supportive care should be provided with monitoring. Dialysis is not a reliable treatment for overdose of lamivudine.
No human trials to date have provided evidence of carcinogenesis, mutagenesis, or fertility impairment.
Proper patient education on dosage, monitoring, and stopping treatment will help improve outcomes. Proper physician education on considerations when prescribing, comorbidities, monitoring, and stopping treatment is also necessary. Care is essential when prescribing the oral solution for pediatric patients due to the possibility of pancreatitis or worsening existing pancreatitis. Consideration is also required when prescribing the correct formula for the proper condition(s). Lower dose lamivudine is indicated for patients with HBV only. If a patient is co-infected with HIV-1, a larger dose of lamivudine is REQUIRED to prevent HIV-1 mutation and resistance. Additionally, co-administered sorbitol containing medicines should be avoided to limit the sub-exposure of medication.
|||Roussos A,Koilakou S,Kalafatas I,Kalantzis C,Apostolou N,Grivas E,Raptis N,Mantzaris G, Lamivudine treatment for acute severe hepatitis B: report of a case and review of the literature. Acta gastro-enterologica Belgica. 2008 Jan-Mar; [PubMed PMID: 18396747]|
|||Quercia R,Perno CF,Koteff J,Moore K,McCoig C,St Clair M,Kuritzkes D, Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. Journal of acquired immune deficiency syndromes (1999). 2018 Jun 1; [PubMed PMID: 29474268]|
|||Haché C,Villeneuve JP, Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert opinion on pharmacotherapy. 2006 Sep; [PubMed PMID: 16925509]|
|||Kumar PN,Patel P, Lamivudine for the treatment of HIV. Expert opinion on drug metabolism [PubMed PMID: 20001611]|
|||Miller V,Stark T,Loeliger AE,Lange JM, The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV medicine. 2002 Apr; [PubMed PMID: 12010361]|
|||Casado JL,Bañón S, Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection. Expert review of clinical pharmacology. 2015; [PubMed PMID: 26517111]|
|||Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet (London, England). 1997 May 17; [PubMed PMID: 9164314]|
|||Radford M,Parks DC,Ferrante S,Punekar Y, Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients. AIDS (London, England). 2019 Sep 1; [PubMed PMID: 31180906]|
|||Cahn P,Andrade-Villanueva J,Arribas JR,Gatell JM,Lama JR,Norton M,Patterson P,Sierra Madero J,Sued O,Figueroa MI,Rolon MJ, Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. The Lancet. Infectious diseases. 2014 Jul; [PubMed PMID: 24783988]|
|||Tan EL,Ooi EE,Lin CY,Tan HC,Ling AE,Lim B,Stanton LW, Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerging infectious diseases. 2004 Apr [PubMed PMID: 15200845]|
|||Johnson MA,Moore KH,Yuen GJ,Bye A,Pakes GE, Clinical pharmacokinetics of lamivudine. Clinical pharmacokinetics. 1999 Jan; [PubMed PMID: 9989342]|
|||Venhoff N,Setzer B,Melkaoui K,Walker UA, Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antiviral therapy. 2007; [PubMed PMID: 18018766]|
|||Whirl-Carrillo M,McDonagh EM,Hebert JM,Gong L,Sangkuhl K,Thorn CF,Altman RB,Klein TE, Pharmacogenomics knowledge for personalized medicine. Clinical pharmacology and therapeutics. 2012 Oct; [PubMed PMID: 22992668]|
|||Dumond JB,Yang KH,Kendrick R,Reddy YS,Kashuba AD,Troiani L,Bridges AS,Fiscus SA,Forrest A,Cohen MS, Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. Antimicrobial agents and chemotherapy. 2015 Oct; [PubMed PMID: 26239974]|
|||Gray LR,Tachedjian G,Ellett AM,Roche MJ,Cheng WJ,Guillemin GJ,Brew BJ,Turville SG,Wesselingh SL,Gorry PR,Churchill MJ, The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PloS one. 2013; [PubMed PMID: 23614033]|
|||Van den Hof M,Blokhuis C,Cohen S,Scherpbier HJ,Wit FWNM,Pistorius MCM,Kootstra NA,Teunissen CE,Mathot RAA,Pajkrt D, CNS penetration of ART in HIV-infected children. The Journal of antimicrobial chemotherapy. 2018 Feb 1; [PubMed PMID: 29126299]|
|||Johnson MA,Verpooten GA,Daniel MJ,Plumb R,Moss J,Van Caesbroeck D,De Broe ME, Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. British journal of clinical pharmacology. 1998 Jul; [PubMed PMID: 9690945]|
|||Benaboud S,Tréluyer JM,Urien S,Blanche S,Bouazza N,Chappuy H,Rey E,Pannier E,Firtion G,Launay O,Hirt D, Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrobial agents and chemotherapy. 2012 Feb; [PubMed PMID: 22106227]|
|||Müller F,König J,Hoier E,Mandery K,Fromm MF, Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochemical pharmacology. 2013 Sep 15; [PubMed PMID: 23876341]|
|||Götte M,Arion D,Parniak MA,Wainberg MA, The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. Journal of virology. 2000 Apr; [PubMed PMID: 10729133]|
|||Perry CM,Faulds D, Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs. 1997 Apr; [PubMed PMID: 9098665]|
|||Lebensztejn DM,Kaczmarski M, Lamivudine-associated thrombocytopenia. The American journal of gastroenterology. 2002 Oct; [PubMed PMID: 12385471]|
|||Zerboni R,Angius AG,Cusini M,Tarantini G,Carminati G, Lamivudine-induced paronychia. Lancet (London, England). 1998 Apr 25; [PubMed PMID: 9643757]|
|||Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS (London, England). 2007 Nov 30; [PubMed PMID: 18025882]|
|||Ba A,Ndiaye FK,Djeng YJ,Cames C,Diack A,N'diaye O, Impact of Highly Active Antiretroviral Therapy on Chronic Hepatitis B Serological Markers among Senegalese HIV Co-infected Children. International journal of MCH and AIDS. 2019; [PubMed PMID: 31824751]|
|||Fischer KP,Gutfreund KS,Tyrrell DL, Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2001 Apr; [PubMed PMID: 11512520]|
|||Sax PE,Tierney C,Collier AC,Fischl MA,Mollan K,Peeples L,Godfrey C,Jahed NC,Myers L,Katzenstein D,Farajallah A,Rooney JF,Ha B,Woodward WC,Koletar SL,Johnson VA,Geiseler PJ,Daar ES, Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. The New England journal of medicine. 2009 Dec 3; [PubMed PMID: 19952143]|
|||Adkison K,Wolstenholme A,Lou Y,Zhang Z,Eld A,Perger T,Vangerow H,Hayward K,Shaefer M,McCoig C, Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study. Clinical pharmacology and therapeutics. 2018 Mar; [PubMed PMID: 29150845]|
|||McComsey GA,Kitch D,Sax PE,Tebas P,Tierney C,Jahed NC,Myers L,Melbourne K,Ha B,Daar ES, Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Jul 15; [PubMed PMID: 21690627]|
|||Staszewski S,Loveday C,Picazo JJ,Dellarnonica P,Skinhøj P,Johnson MA,Danner SA,Harrigan PR,Hill AM,Verity L,McDade H, Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA. 1996 Jul 10; [PubMed PMID: 8656502]|